Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for eczema patients when first treatment fails

NCT ID NCT05369403

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called lebrikizumab in 86 adults and teens with moderate-to-severe eczema who had already tried dupilumab. The goal was to see if lebrikizumab could safely improve their skin condition. Researchers measured how many participants achieved at least a 75% improvement in eczema severity after 16 and 24 weeks of treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

86 people

The number who actually took part.

Started

Dec 2022

Finished

Feb 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All participants must have prior treatment with dupilumab meeting one of the following conditions: * Participants who stopped dupilumab treatment due to non-response, partial response, loss of efficacy must have been previously treated with dupilumab (at labeled dose level) for at least 4 months. * Participants who stopped dupilumab treatment due to intolerance or adverse events (AEs) to the drug may enter the study with no required prior length of dupilumab treatment. * Participants who stopped dupilumab treatment due to cost or loss of access to dupilumab (for example, insurance coverage) may enter the study with no required prior length of dupilumab treatment. * Participants who have chronic AD that has been present for ≥1 year before screening. * Have EASI ≥16 at baseline * Have IGA score ≥3 (Scale of 0 to 4) at baseline * Have ≥10% body surface area (BSA) of AD involvement at baseline * Have a history of inadequate response to treatment with topical medications; or determination that topical treatments are otherwise medically inadvisable. * Adolescents body weight must be ≥40 kg at baseline. Exclusion Criteria: * History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening. * Have a current infection or chronic infection with hepatitis B virus (HBV) at screening (that is, positive for hepatitis B surface antigen and/or polymerase chain reaction positive for HBV DNA * Have a current infection with hepatitis C virus (HCV) at screening (that is, positive for HCV RNA * Have an uncontrolled chronic disease that might require multiple intermittent uses of oral corticosteroids at screening, as defined by the investigator. * Have uncontrolled asthma that * might require bursts of oral or systemic corticosteroids, or * required the following due to ≥1 exacerbations within 12 months before baseline * systemic (oral and/or parenteral) corticosteroid treatment, or * hospitalization for \>24 hours. * Have known liver cirrhosis and/or chronic hepatitis of any etiology. * Had Dupilumab treatment within 4 weeks prior to baseline * Had prior treatment with tralokinumab. * Treatment with topical agents: corticosteroids, calcineurin inhibitors, Janus Kinase (JAK) inhibitors, or phosphodiesterase-4 inhibitors, such as crisaborole within 2 weeks prior to baseline * Treatment with any of the following agents within 4 weeks prior to the baseline * systemic immunosuppressive or immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate mofetil, IFN-gamma, azathioprine, methotrexate, and other immunosuppressants) * small molecules (e.g. JAK inhibitors) * phototherapy and photochemotherapy for AD

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atopic dermatitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema Eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atopic dermatitis

Contacts and locations

Locations

  • Advanced Medical Research

    Sandy Springs, Georgia, 30328, United States

  • Allcutis Research, Inc

    Portsmouth, New Hampshire, 03801, United States

  • Allcutis Research, Inc.

    Beverly, Massachusetts, 01915, United States

  • Avance Clinical Trials Inc

    Laguna Niguel, California, 92677, United States

  • Axon Clinical Research

    Inglewood, California, 90301, United States

  • Clinical Partners, LLC

    Johnston, Rhode Island, 02919, United States

  • Clinical Science Institute

    Santa Monica, California, 90404, United States

  • Complete Dermatology

    Sugar Land, Texas, 77479, United States

  • Cura Clinical Research

    Sherman Oaks, California, 91403, United States

  • Dawes Fretzin Clinical Research Group, LLC

    Indianapolis, Indiana, 46250, United States

  • Dermatologists of Greater Columbus

    Bexley, Ohio, 43209, United States

  • Dermatology Research Associates

    Los Angeles, California, 90045, United States

  • Dermatology and Advanced Aesthetics

    Lake Charles, Louisiana, 70605, United States

  • Dermatology and Skin Cancer Specialists, LLC

    Rockville, Maryland, 20850, United States

  • Dermatology and Skin Surgery Center, PC

    Exton, Pennsylvania, 19341, United States

  • Direct Helpers Research Center

    Hialeah, Florida, 33012, United States

  • Dundee Dermatology

    West Dundee, Illinois, 60118, United States

  • Encore Medical Research of Boynton Beach

    Boynton Beach, Florida, 33436, United States

  • First OC Dermatology

    Fountain Valley, California, 92708, United States

  • Hollywood Dermatology

    Hollywood, Florida, 33021, United States

  • MediSearch Clinical Trials

    Saint Joseph, Missouri, 64506, United States

  • Medical Dermatology Specialists

    Phoenix, Arizona, 85006, United States

  • Miami Dermatology and Laser Research

    Miami, Florida, 33173, United States

  • Oakland Hills Dermatology

    Auburn Hills, Michigan, 48326, United States

  • Olympian Clinical Research

    Tampa, Florida, 33615, United States

  • OptiSkin Medical

    New York, New York, 10128, United States

  • Revival Research Institute - Troy

    Troy, Michigan, 48084, United States

  • River Region Dermatology and Laser

    Montgomery, Alabama, 36117, United States

  • Sadick Research Group

    New York, New York, 10075, United States

  • Skin Care Physicians of Georgia

    Macon, Georgia, 31217, United States

  • Spokane Dermatology Clinic

    Spokane, Washington, 99202, United States

  • The Derm Institute of West Michigan

    Caledonia, Michigan, 49316, United States

  • Total Vein and Skin LLC

    Boynton Beach, Florida, 33437, United States

  • UConn Health

    Farmington, Connecticut, 06030-2840, United States

  • Wallace Medical Group, Inc.

    Los Angeles, California, 90056, United States

  • Windsor Dermatology, P.C.

    East Windsor, New Jersey, 08520, United States

  • Ziaderm Research, LLC.

    North Miami Beach, Florida, 33162, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.